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Background: Gait impairment is common in people with Parkinson’s disease. There is a lack of effective interventions
to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying
cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson’s disease. The combined
impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this
trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with
established Parkinson’s disease.
Methods/design: This is a single centre, double-blind, randomised placebo-controlled trial in 130 people with
Hoehn and Yahr stage 2–3 idiopathic Parkinson’s disease who have fallen in the past year. Participants will be
randomised to two groups, receiving either rivastigmine capsules or identical placebo capsules for 8 months.
Assessment will be undertaken at baseline and at the end of medication prescription (i.e. 8 months) with
participants remaining enrolled in the trial for a further 4 months to monitor for falls and adverse events. The
primary outcome is step time variability, assessed with and without the addition of concurrent cognitive tasks.
Secondary outcomes will include other gait parameters, sensorimotor and balance performances, cognitive
indices, falls and fall related injury, fear of falling, Parkinson’s symptoms and data pertaining to possible harms.
Discussion: This randomised controlled trial will examine the effect of cholinesterase inhibitor therapy on gait, balance
and falls in Parkinson’s disease. If effective, it would offer a new therapeutic option to ameliorating gait and cognitive
deficits in a population at high risk of falls.
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Falls are a common and devastating complication of
Parkinson’s disease (PD). Whilst tremor, akinesia and ri-
gidity are early motor manifestations, postural instability
tends to emerge as the disease progresses. Postural in-
stability, coupled with gait dysfunction, is a major deter-
minant of disability [1] with mobility and walking
limitation cited by patients as the worst aspect of the
disease [2]. Falls are a cause of significant morbidity.
The consequences include fractures and injuries [3], fear
of falling [4], nursing home and hospital admission
[5] carer strain [6] and increased mortality [7]. Gait
impairment, postural instability and falls are common
complications of PD and may have a greater impact
on quality of life than motor complications and dyskinesia
[8]. There is currently a lack of pharmacological op-
tions of proven efficacy for addressing falls, postural
instability, freezing of gait and festination in this high
risk population.
The burden of disease complications will inevitably in-
crease as the number of people with Parkinson’s disease
in the most populous nations is expected to double from
2005 to 2030 [9]. A meta-analysis of prospective studies
exploring falls in people with Parkinson’s disease demon-
strated that 46% of individuals fall at least once over a
period of three months [10]. Twenty years from diagno-
sis, 87% of people with Parkinson’s disease in the Sydney
cohort had fallen with 35% sustaining a fracture [11].
The peak risk of falls corresponds with Hoehn and Yahr
stage three [12] where people are still mobile but have
reduced stability.
Despite increasing recognition of the non-motor fea-
tures of the disease, the mainstay of pharmacological
therapy remains dopaminergic medications. However,
disorders of gait and balance in PD are not generally
ameliorated by typical dopaminergic medication. During
the maintenance and early complications phase of the
disease, gait disturbances and end of dose freezing, typ-
ically respond to dopaminergic agents. As the condition
progresses with associated motor complications, re-
sponse to treatment becomes less predictable and freez-
ing may develop in the “on” stage [13]. As Parkinson’s
disease advances, “off” freezing becomes unpredictable
despite optimisation of medical therapy and levodopa-
induced dyskinesias and ‘on’ freezing further contribute
to the risk of an individual falling.
Characterisation of the cholinergic neurochemical def-
icit that is thought to underlie gait disorders and pos-
tural instability has aided the search for potential
therapeutic targets. The predominantly cholinergic ped-
unculopontine nucleus (PPN) provides input into the
basal ganglia and cortex and undergoes degeneration in
PD. The extent of degeneration is correlated with the
degree of gait dysfunction [14]. Cortical and thalamiccholinergic loss, representing projections from the nu-
cleus basalis of Meynert (nbM) and the PPN respect-
ively, is significantly greater in people with PD and a
history of falls compared to both those without falls and
non-PD controls [15]. Similarly, the degree of choliner-
gic neuronal loss is negatively correlated with the Hoehn
and Yahr score, which is driven by the progressive emer-
gence of axial impairment [16].
Outside of a potential role in gait dysfunction, cholin-
ergic loss manifests as an alteration in attention and cog-
nition [17]. Furthermore mild cognitive impairment
(MCI) is highly prevalent in people with PD and in-
creases with age, duration and severity of PD and affects
a range of cognitive domains [18]. The nbM is the main
source of cholinergic projections to the cerebral cortex
and degenerates in PD [19]. Greater cholinergic neur-
onal loss in the nbM is seen in people with Parkinson’s
disease dementia (PDD) than in PD [20], and neuroim-
aging evidence of this cholinergic dysfunction is present
early in the disease course [21].
The observed deficit in cholinergic function in Parkin-
son’s disease thus accounts, at least to some degree, for
the dysfunction seen in both cognitive and gait domains.
Historically, gait has been regarded as demanding little
or no cognitive resources. The dual-task technique pro-
vides a means to examine the extent to which different
activities demand attentional capacity, i.e. draw on com-
mon central processing resources. In dual-task experi-
ments, a decrement in performance occurring when two
tasks are performed simultaneously (relative to baseline
performance on each single task) indicates that both
tasks demand attention [22].
Dual-task paradigms have revealed important insights
into the relationship between gait and cognition. Dual-
task conditions augment gait impairments seen during
normal walking in PD such as reduction in gait speed,
stride length and increased stride-to-stride variability
[23]. Furthermore, in PD, a ‘posture second’ strategy
seems to be adopted whereby individuals are unable to
appropriately prioritise the safety of their walking above
other cognitive demands [24].
Despite evidence that cholinergic loss may influence
both gait and cognitive changes, few have studied the ef-
fect of cholinergic augmentation on gait, balance and
falls. A small trial of six individuals with Alzheimer’s dis-
ease (AD) versus eight controls with MCI examined the
effect of a 4 month period of treatment with the acetyl-
cholineseterase inhibitor donepezil. This demonstrated
that both gait velocity and variability improved under
single and dual-task conditions at follow-up [25]. Two
further studies showed an improvement in stride time
[26] and a reduction in falls with treatment [25,27]. A
further RCT is currently underway examining these ef-
fects on a larger cohort of individuals with MCI [28]. In
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showed a reduction in fall rate, though this was driven
primarily by reductions in only those with a history of
very frequent falls [27].
The aim of this randomised controlled trial is to exam-
ine the effect of cholinesterase inhibitor therapy on gait
and balance and fall risk in people with Parkinson’s dis-
ease with a history of one or more falls in the past year.
Methods
Design
A placebo-controlled double blind, randomised clinical
trial (RCT) using a parallel arm design (Figure 1).
Participants and setting
Participants will be eligible if they meet the following in-
clusion criteria; a) have moderate Parkinson’s disease
(Hoehn and Yahr stage 2–3), b) have fallen in the last
year, c) are able to walk without aids for the distance of
the walking protocol (approximately 18 metres), d) have
been stable on anti-Parkinsonian medication for 2 weeksIdentifi
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Figure 1 Trial flow diagram.prior to enrolment and e) are able to give informed con-
sent. Potential participants will be excluded if they: a)
have any other cause contributing to their Parkinsonian
features (vascular disease, multisystem atrophy (MSA),
progressive supranuclear palsy (PSP), normal pressure
hydrocephalus), b) have a known diagnosis of dementia,
c) have other neurological, visual or orthopaedic prob-
lems that significantly interfere with balance or gait, d)
have had previous or current treatment with a cholin-
esterase inhibitor or an absolute contraindication to cho-
linesterase inhibitor therapy, e) are unable to attend or
comply with treatment or follow-up scheduling and
f) are non-English speaking as cognitive tests will be
performed in English.
Ethical approval was granted from the South West
Research Ethics Committee on 28th September 2011 and
the Medicines and Healthcare Regulatory Agency
(MHRA) on 18th June 2012.
Participants will be identified from centres in the
South West of England and South East Wales by
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Henderson et al. BMC Neurology 2013, 13:188 Page 4 of 10
http://www.biomedcentral.com/1471-2377/13/188(Dementias and Neurodegenerative Diseases Research
Network) and via advertising through the Parkinson’s
Disease-UK charity. Participants will also be identified
through National Health Service (NHS) Trusts acting as
Participant Identification Centres (PICs) predominantly in
neighbouring regions of South West England. The trial is
a single site study based in a NHS Trust hospital.
Participants will be sent or given an information pack
that provides further details about the study and asked
to return a reply slip indicating their interest in taking
part. Interested participants will be screened by tele-
phone and offered an appointment if they meet the in-
clusion criteria. Written informed consent will be
obtained from all participants.Randomisation and blinding
After confirming eligibility and obtaining informed con-
sent, participants will be randomised to one of two treat-
ment arms. Both the assessors and participants will be
blinded to the treatment allocation throughout the trial.
Unblinding will occur once all assessments are complete
and the database has been locked at the end of the trial.
The randomisation sequence will be generated by Bristol
Randomised Trials Collaboration (BRTC) clinical trials
unit. We will use a minimisation algorithm with a ran-
dom element to ensure that the two trial arms are simi-
lar on three key variables: age, cognitive impairment
(using the Montreal Cognitive Assessment (MOCA))
and number of falls sustained in the past year. The list
will be generated by a web based program which then is-
sues a treatment pack number that is matched to a drug
package held in the pharmacy, thereby ensuring conceal-
ment of allocation.Assessment procedures
Participants will visit the hospital on two occasions to
undergo assessment, at baseline and after 32 weeks of
treatment. The baseline visit will involve checking eligi-
bility against the inclusion and exclusion criteria and ad-
ministering questionnaires relating to sociodemographic
and general health measures. Assessment of physical
and cognitive function, a physical examination and re-
cording of an electrocardiogram will also be undertaken.
If eligible and willing to participate, informed consent
will be obtained and participants will be randomised at
this stage.
At both visits, assessments will include cognitive tests,
analysis of fall risk, and gait and balance testing. Falls
and adverse event data will be ascertained by monthly
follow-up phone calls. Visit 2 will additionally involve
ascertainment of osteoporosis risk factors and measure-
ment of frailty status to reduce the assessment burden
for visit 1. Table 1 illustrates the assessments performedat each visit and whether these are primary or secondary
outcome measures.
Intervention
Participants will receive either rivastigmine or an identi-
cally matched placebo in treatment packs at visit one.
They will be instructed to take one tablet twice a day.
All participants will up-titrate the dose every four weeks
(1.5 mg, 3 mg, 4.5 mg and 6 mg rivastigmine or matched
placebo) over a 16 week period. This slower four week
up-titration schedule has been adopted in other clinical
trials on the basis of optimising tolerability [45,46]. The
up-titration phase will be followed by a 16 week main-
tenance dose period after which time the medication will
be stopped, yielding a total treatment period of 32 weeks
(Figure 2). In the event of unacceptable side effects oc-
curring, participants will be instructed to down-titrate to
the last tolerated dose or stop the medication according
to clinical judgement.
Primary outcome measure - step time variability
The primary outcome measure will be step time variabil-
ity assessed in three walking conditions: normal walking,
(b) walking while performing a verbal fluency task and
(c) walking while performing a verbal fluency switching
task. Variability will be calculated according to current
recommendations [47] as both the standard deviation
(SD) and the coefficient of variation (CoV) (SD/mean x
100%). The SD for the three walking conditions will be
reported as the primary outcome measure, though we
hypothesise a priori that any observed differences will be
magnified with increasing cognitive demands. Each con-
dition is repeated three times for a total of nine walks.
Gait will be assessed with an accelerometer, housed in a
small, lightweight (5 g) container attached to the partici-
pant’s waist with an elasticated belt (Dynaport Hybrid
system, McRoberts). Participants will be tested whilst in
the ‘on’ medication state and will be instructed to walk
at self-selected speeds over a 22 m obstacle-free level
corridor, wearing their normal footwear and clothing.
During the dual-task conditions, participants will not be
given instructions as to which task to prioritise. The ver-
bal fluency task is based on the controlled oral word as-
sociation test (COWAT) whereby participants are asked
to name as many words as they can beginning with a
given letter of the alphabet. The switching dual-task is a
more challenging version of COWAT. Participants are
instructed to switch alternately between words beginning
with two different letters of the alphabet. Letters are se-
lected based on their frequency in the English dictionary
and thus perceived difficulty. The three walking condi-
tions will be randomly ordered to minimise practice ef-
fects. In the event of a failure on either the cognitive
task or walking the participant will be prompted to
Table 1 Assessments at baseline (BA) and at follow-up (FUA) indicating primary (1°) and secondary (2°) outcomes (O)
BA FUA O
Sociodemographics
Marital status, education, occupation, socioeconomic status, gender, ethnicity ✓ x x
General health and function
Past medical and Parkinson’s disease history, medication use, social history (place and type of residence, help with activities of daily
living, smoking, alcohol use, use of walking and visual aids)
✓ ✓ x
Osteoporosis risk factors are recorded according to the WHO Fracture Risk Assessment Tool (FRAX tool) [29] and the QFRACTURE [30]
risk algorithm.
x ✓ x
Measurement of frailty status using the CSHA Clinical Frailty Scale [31] and the criteria proposed by Fried et al. [32] measuring weight
loss, physical activity, grip strength, walk speed and self-reported fatigue.
x ✓ x
Self-reported physical activity measured using the Physical Activity Scale for the Elderly (PASE) [33] x ✓ x
Quality of life
ED-5D-5 L is widely used quality of life instrument which can be used for estimating QALYs for economic evaluations [34]. ✓ ✓ 2°
Cognitive assessments
Cognition will be assessed using the Montreal Cognitive Assessment (MOCA) [35] ✓ ✓ 2°
Cognitive Failures Questionnaire (CFQ) [36] ✓ ✓ 2°
Test Your Memory (TYM) [37] ✓ ✓ x
Frontal Assessment Battery (FAB) [38] ✓ ✓ 2°
The 15 item Geriatric Depression Score will be used to measure mood [39]. ✓ ✓ 2°
Physical assessment
Physical examination and electrocardiogram ✓ x x
Gait assessment using triaxial accelerometer with and without concurrent cognitive tasks ✓ ✓ 1°
Freezing of gait will be assessed with the specific gait task designed to elicit freezing as well as the Freezing of Gait Questionnaire
[40].
✓ ✓ 2°
Coordinated stability – a measure of controlled leaning balance [41]. ✓ ✓ 2°
Physiological Profile Assessment containing 5 validated measures of physiological function: visual contrast sensitivity, proprioception,
quadriceps strength, simple reaction time, and postural sway while standing on a foam rubber mat with eyes open [42].
✓ ✓ 2°
Parkinson’s disease fall risk score comprised of 3 validated measures quadriceps strength, coordinated stability and freezing of gait
[43].
✓ ✓ 2°
Parkinson’s disease severity will be measured using the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale [44]. ✓ ✓ 2°
Falls, resultant injuries and adverse events
Falls, injuries and use of medical services will be collected by monthly phone calls and diaries. ✓ ✓ 2°
Adverse events will be screened for during monthly follow-up phone calls ✓ ✓ 2°
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In addition to step time variability, we will assess the effects
of the intervention on a number of other gait parameters:
harmonic ratios, velocity (m/s), cadence (steps/min), step
length (cm), stance time (sec), stance time variability,
double limb support (% of gait cycle) and walk ratio (see
Appendix 1 for more details).
Freezing of gait will be assessed by asking participants
to stand from a chair, walk between two chairs placed
50 cm apart, turn 360° to the right, 540° to the left and
then walk back the same way and return to the chair.The walks will be videotaped to classify the type and
duration of any freezing episodes. Freezing of gait will be
also measured using the FOG questionnaire [40].
Controlled leaning balance
Controlled leaning balance will be assessed with the coordi-
nated stability test which requires participants to accurately
adjust their position in a steady and coordinated manner
when their centre of mass is near the limits of their base of
support [41].
Fall risk indices
Fall risk will be assessed with two validated mea-
sures - the short-form Physiological Profile Assessment
(PPA) [42] and the Parkinson’s disease fall risk index
(PDFRI) [48].
Figure 2 Schedule of assessment visits, medication titration and monitoring of adverse events and falls.
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performance including (1) visual contrast sensitivity, (2)
proprioception, (3) quadriceps muscle strength, (4) hand
reaction time and (5) postural sway. Visual contrast sen-
sitivity is assessed using the Melbourne Edge Test. The
chart has 20 circular patches containing edges with re-
ducing contrast with variable orientation as the identify-
ing feature. Correct identification of the orientation of
the edge on the patches provides a measure of contrast
sensitivity in decibel units, where 1 dB = 10 log10 con-
trast. Proprioception is measured using a lower-limb
matching test, where difference in matching the great
toes in degrees is recorded using a vertical clear acrylic
sheet inscribed with a protractor and placed between the
legs. Quadriceps muscle strength (isometric) in kilo-
grams is examined in the dominant leg using a spring
gauge while participants are seated with the hip and the
knee joint at 90° of flexion. Simple reaction time in milli-
seconds is assessed using a light as a stimuli and a
finger-depression of a switch as the response. Postural
sway (total sway path in millimeters) is assessed using a
swaymeter that measures the displacement of the body
at waist level while participants stand for 30 seconds on
a foam rubber mat with eyes open. The five PPA compo-
nents are weighted to compute a composite PPA fall risk
score which has been shown to prospectively discrimin-
ate between older fallers and non-fallers with an accur-
acy up to 75% [42].
The complementary PDFRI is calculated from an
algorithm comprising measures of gait freezing, ab-
normal posture, executive functioning, coordinated
stability and lower limb weakness. In a study of 113
participants with PD this index discriminated betweenfallers and non-fallers with a sensitivity of 77% and a
specificity of 82% [48].
Cognitive assessment, mood and quality of life
Cognition will be measured using the Montreal Cogni-
tive Assessment (MOCA) [49], Cognitive Failures Ques-
tionnaire (CFQ) [36], Test Your Memory (TYM) tool
[37], Frontal Assessment Battery (FAB [38]), and verbal
fluency performance assessed whilst seated using the
COWAT (described above). Fear of falling will be quan-
tified using the short version of the Iconographical Falls
Efficacy Scale (Icon-FES) [50], mood will be assessed
with the 15 item Geriatric Depression Score [39] and
quality of life will be assessed using EQ-5D-5L [34].
Parkinson’s disease symptoms
Parkinson’s disease symptoms and stage will be assessed
using the new Unified Parkinson’s Disease Rating Scale
[44] (UPDRS) which incorporates a patient completed
non motor and motor aspects of daily living, a clinician
completed assessment of motor complications and re-
sults of a motor examination.
Falls
Falls and resultant injuries will be assessed as the num-
ber and rate of falls, proportion of fallers in each group,
injury and injury related healthcare use. A fall will be
defined as “an unexpected event in which participants
come to rest on the ground, floor, or lower level” [51].
Falls will be recorded with falls diaries. All participants
will receive monthly calendars on entry to the study
which are returned in pre-paid envelopes to the research
personnel. The calendars record the number of falls in a
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stances for each fall. Participants will also be routinely
telephoned monthly to verify any falls data and be
screened for other adverse events.Safety
Participants will be asked to notify the research team by
phone if they experience any adverse events. Addition-
ally, all participants will be screened during the monthly
phone calls for adverse events using an open ended,
non-leading question. Serious adverse events will be
defined as events that result in death, hospitalisation
(except for a pre-existing condition that had not wors-
ened), significant disability or incapacity.
Potential worsening of extrapyramidal symptoms has
been previously cited as a concern when prescribing
cholinesterase inhibitors in Parkinson’s disease. A large
multicentre placebo controlled trial of 541 people with
mild to moderate dementia related to Parkinson’s disease
demonstrated improvement in cognitive scores [45].
Worsening of tremor is a recognised side effect of rivas-
tigmine but was only sufficiently severe to cause with-
drawal of 1.7% of patients treated in the aforementioned
trial. Monthly phone calls and access to the trial team
should facilitate rapid reporting of such symptoms and
appropriate down titration or cessation of the drug
where clinically appropriate.
Adherence will be measured with a pill count of
returned medications. This will be compared with the
participant’s reported adherence on the basis of informa-
tion ascertained during the follow-up phone calls and at
the second face-to-face assessment visit.Sample size
As there are no data on the effect of rivastigmine treat-
ment on step time variability, our sample size calculation
has been estimated by extrapolating from related studies.
For example, it has been found that treatment with
donepezil resulted in a reduction in gait variability (22.3
to 11.3% CoV) for AD patients in a non-randomized
trial [25].
Pragmatically, we estimate that we can recruit 130 eli-
gible participants for the study over a 12 month period.
Assuming a 30% drop out (based on a previous RCT
[45]) this would result in approximately 90 patients (45
per arm) with trial data. This will enable us to detect a
treatment effect difference of 0.6 standardised (z-score)
units for our primary outcome measure (step time vari-
ability) with 80% power and at a two-sided 5% signifi-
cance level. This sample size is similar to a study
currently being undertaken in non-PD patients with
mild cognitive impairment, i.e. 140 participants [28].
The use of a dual-task paradigm, as a cognitive stressor,may produce a more sensitive measure of any treatment
benefit.
The clinical impact of such a group difference in gait
variability can be estimated from a study by Maki [52].
In a cohort of 75 elderly volunteers without PD, a 0.6
standardised difference in stride velocity and stride
length was associated with a 1.65 and 1.50 increased
odds ratio of falling respectively, which would translate
into clinically important benefits. We have assumed that
these results will generalize to PD populations, and also
manifest in step time variability, possibly a better pre-
dictor of fall risk in this population [53].
Statistical analysis
Simple descriptive statistical analyses will initially be
undertaken on all outcomes measures. For continuous
measures (e.g. step time, step length and variability) the
mean, SDs and distributions will be examined. Where
measures are skewed, transformation will be undertaken.
Outcome data on falls will be analysed by: (i) number of
falls (count), (ii) non-fallers, low frequency of falls and
frequent fallers (categorical ordinal variable), (iii) fall rate
per person month (rate) and (iv) proportion of fallers in
each group. Injury data will be summarized as (i) periph-
eral fracture rate per person-year of follow-up, (ii) num-
ber of peripheral fractures, (iii) number of people
sustaining peripheral fractures, and (iv) number of
people sustaining multiple events. For these variables,
frequency counts (e.g. categorical variables) or Kaplan
Meier plots for survival time variables will be analysed.
Other binary or categorical measures (such as adverse
event data) will be examined by simple frequency counts
and contingency tables with Chi2 tests of association.
The main analyses will be performed using the
intention to treat principle. For the primary outcome
measure (step variability), we will use multivariable lin-
ear regression models and adjust for baseline or other
covariates to increase precision. Hence we will compare
group differences at 32 weeks in the gait variability pa-
rameters conditional on baseline parameters. For the
secondary outcomes we can use ordinal logistic regres-
sion (e.g. for frequency of falls as an ordinal variable),
Cox’s proportional hazard model for time to first fall
and negative binomial regression to compare fall rates
between groups. The last method accounts for falls clus-
tering within participants, and has been recommended
for falls data analysis [54]. The baseline covariates will
be adjusted for as appropriate.
For participants who fail to complete the follow-up,
sensitivity analyses will be undertaken, using multiple
imputation methods. There are no planned interim
analyses and no formal adjustments will be used for
multiple testing though we will be cautious in our inter-
pretation of the secondary outcomes (especially when
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given the possibility of type I errors.
Discussion
Falls and the consequences thereof are devastating to
people with Parkinson’s disease. This trial will provide
new insight into the effect of cholinesterase inhibitors on
gait, balance and fall risk in this vulnerable group. It will
establish and further validate falls prediction algorithms
and delineate the interaction of multiple key risk factors
that contribute to the high rate of falls that occur in this
vulnerable population. Rivastigmine could potentially
represent a safe and cost effective therapeutic approach to
treating gait and balance dysfunction in Parkinson’s
disease utilising an already established pharmacological
agent. Hence, this may offer an effective, acceptable inter-
vention in an area of Parkinson’s disease where there are
currently unmet symptom needs and little in the way of
evidence based therapeutic strategies.
Appendix 1
The gait parameter definitions are described in Table 2.
Step time variability is the primary outcome measure.
The effect of the intervention will be measured on the
other gait parameters listed.Table 2 Gait parameter definitions used in the ReSPonD trial
Gait parameter Definition
Stride One stride equals two
Stride time Time taken for one stri
Stride length Distance traversed by
Step Defined by consecutiv
Step time Time taken for one ste
Step length Distance between con
number of steps taken
Walking speed The velocity of walking
Variability Variability of the measu
coefficient of variation
Double limb support The period for which b
until toe off of the con
Cadence (steps/min), The number of steps p
Stance time (sec) Duration of stance tim
Walk ratio The relationship betwe
walking. Calculated as
Harmonic ratios (AP and VT) The ratio of even/odd
movements repeat eac
repeat twice per stride
Harmonic ratios (Matthew Brodie, personal
communication, October 24th 2013)
The ratio of even/odd
repeat each stride. Stab
two gait cycles as mea
define the fundamentaCompeting interests
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de
two steps
e heels strikes of contralateral limbs
p
secutive heel strikes, mean is calculated by the distance travelled /
.
, calculated as the distance travelled / time taken.
re of interest, expressed as the standard deviation (SD) and the
(CoV) = SD/mean x 100%.
oth feet are in contact with the floor, calculated by time from heel strike
tralateral limb.
er minute
e (single and double support) in one gait cycle.
en the amplitude and frequency of the rhythmic leg movements when
step length / cadence.
harmonics of acceleration over one gait cycle. In gait, AP and VT
h step. Stable gait therefore contains more AP and VT accelerations that
as measured by even harmonics in the frequency domain.
harmonics of acceleration over two gait cycles. In gait, ML movements
le gait therefore contains more ML accelerations that repeat twice every
sured by even harmonics in the frequency domain when two strides
l harmonic.
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